Oncolytic viruses exploit common molecular changes in cancer cells, which are not present in normal cells, to target and kill cancer cells. Ras transformation and defects in type I interferon (IFN)-mediated antiviral responses are known to be the major mechanisms underlying viral oncolysis. Previously, we demonstrated that oncogenic RAS/Mitogen-activated protein kinase kinase (Ras/MEK) activation suppresses the transcription of many IFN-inducible genes in human cancer cells, suggesting that Ras transformation underlies type I IFN defects in cancer cells. Here, we investigated how Ras/MEK downregulates IFN-induced transcription. By conducting promoter deletion analysis of IFN-inducible genes, namely guanylate-binding protein 2 and IFN gamma inducible protein 47 (Ifi47), we identified the IFN regulatory factor 1 (IRF1) binding site as the promoter region responsible for the regulation of transcription by MEK. MEK inhibition promoted transcription of the IFN-inducible genes in wild type mouse embryonic fibroblasts (MEFs), but not in IRF1 − / − MEFs, showing that IRF1 is involved in MEK-mediated downregulation of IFN-inducible genes. Furthermore, IRF1 protein expression was lower in RasV12 cells compared with vector control NIH3T3 cells, but was restored to equivalent levels by inhibition of MEK. Similarly, the restoration of IRF1 expression by MEK inhibition was observed in human cancer cells. IRF1 re-expression in human cancer cells caused cells to become resistant to infection by the oncolytic vesicular stomatitis virus strain. Together, this work demonstrates that Ras/MEK activation in cancer cells downregulates transcription of IFN-inducible genes by targeting IRF1 expression, resulting in increased susceptibility to viral oncolysis.
INTRODUCTION
Oncolytic viruses preferentially replicate within cancer cells, leading to their destruction, while normal cells remain unharmed. Although the concept of oncolytic viral therapy has been studied for a century, recent advances in molecular virology and cell biology have brought oncolytic viral therapy to the forefront of cancer therapies. As the outcomes of animal studies and early stage clinical trials are very promising, a few viruses are currently, or will be under evaluation, in phase III clinical trials. 1 Oncolytic viruses exploit tumor-specific molecular changes in cancer cells for their replication such as p53 deficiency, 2 oncogenic Ras activation 3 and defects in the type I interferon (IFN)-induced antiviral response. 4, 5 Nevertheless, despite its promise in clinical application, the precise molecular mechanisms supporting viral oncolysis remain incompletely understood.
Ras-dependent oncolysis was first reported as the mechanism allowing oncolytic reovirus infection. 3 Constitutive Ras activation in transformed cells was shown to be a pre-requisite for the replication of oncolytic reovirus. Since then, the efficacy of reovirus in cancer treatment has been extensively studied both in animal models and in clinical settings, making reovirus a promising anti-cancer agent. 6 Following the discovery of Rasdependent oncolysis by reovirus, other viruses were found to similarly exploit the activated Ras signaling pathway for their oncolysis. [7] [8] [9] [10] [11] [12] Multiple cellular mechanisms have been identified that underlie the Ras dependent viral oncolysis. 3, 11, 13 Another novel concept of viral oncolysis is the exploitation of IFN defects in cancer cells by IFN-sensitive viruses. 4 Insensitivity of cancer cells to IFN has been known as one of the major obstacles of IFN therapy in cancer patients. 14 4 demonstrated that cancer cells generally have lower sensitivity to IFN than normal cells. A common strategy in designing oncolytic viruses is to disarm their anti-IFN viral proteins in wild type viruses such that they exploit IFN deficiency to selectively replicate in cancer cells.
We and others previously reported that activation of the Ras/ Mitogen-activated protein kinase kinase (MEK) pathway suppresses the host antiviral response induced by IFN, [15] [16] [17] clearly demonstrating that the two major mechanisms of viral oncolysis (Ras-dependency and IFN-deficiency) are indeed connected. By conducting microarray analysis using human cancer cells, we further identified the presence of a group of IFN-inducible genes (MEK-downregulated IFN-inducible (MDII) genes), which are induced commonly by IFN and by the MEK inhibitor U0126. 18 These results suggest that transcriptional dysregulation of MDII genes in human cancer cells is one of the underlying mechanisms of Ras-dependent viral oncolysis. Here, we sought to clarify the precise mechanism of how Ras/MEK suppresses transcription of the MDII genes.
RESULTS

Ras/MEK downregulates expression of MDII genes in RasV12 cells
We previously reported a group of IFN-inducible genes which can be downregulated by Ras/MEK (MDII genes) in human cancer cells. 18 To clarify the molecular mechanisms underlying the downregulation of IFN-inducible genes by Ras/MEK, we analyzed global gene expression in RasV12 transformed NIH3T3 (RasV12) cells, which do not have the confounding mutations that occur in human cancer cells. To identify the MDII genes in the mouse fibroblast system, the gene expression profiles of RasV12 cells treated with U0126, IFN or left untreated were determined using DNA microarrays ( Figure 1a ). We identified 1264 genes and 1258 genes with ⩾ 2.5-fold increased expression by either U0126 or IFN treatment, respectively (listed in Supplementary Dataset S1). Furthermore, we identified 619 genes that were upregulated by both MEK inhibition and IFN treatment as the responsive MDII genes in mouse fibroblast cells.
Based on the microarray data, the expression changes of a subset of genes (guanylate-binding protein 2 (Gbp2), IFN gamma inducible protein 47 (Ifi47), IFN-induced protein with tetratricopeptide repeats 1 (Ifit1), immunity-related GTPase family M member 2 (Iigp2), interleukin 15 (Il15), pentraxin related gene (Ptx3), retinoic acid-inducible gene 1 (Rig-I), signal transducer and activator of transcription 2 (Stat2) and XIAP associated factor 1 (Xaf1)) were selected for validation by reverse transcription polymerase chain reaction (RT-qPCR) analysis ( Figure 1b ).
The expression of Gbp2, Ifi47, Il15, Rig-I, Stat2 and Xaf1 genes were significantly induced by U0126 only and IFN only treatment, and identified as MDII genes. Interestingly, combined treatment of IFN and U0126 significantly increased expression of Gbp2, Il15 and Stat2 compared with those in cells treated with IFN only or U0126 only, suggesting synergistic activation of their transcription by IFN and MEK inhibition. Iigp2 and Ifit1, which were induced only by IFN treatment but not by U0126, represent non-MDII IFN-inducible genes. In contrast, Ptx3, which was induced by U0126, but not by IFN, represents a non-MDII MEK-downregulated gene.
Ras/MEK suppresses the transcription of MDII genes To further determine whether Ras/MEK regulates the MDII gene transcription, we conducted promoter gene analysis for a subset of MDII genes. RasV12 cells were transfected with the pGL3-Basic vector containing the promoter region of either the Gbp2, Ifi47 or Rig-I genes, or the IFN-stimulated response element (ISRE) and then treated with U0126 or IFN for 24 h (Figure 2a ). We found that IFN treatment significantly activated transcription of the ISRE reporter construct and all the reporter constructs containing the MDII gene promoter region. MEK inhibition significantly increased the promoter activity of Gbp2, Ifi47 and ISRE in RasV12 cells. Although Rig-I promoter activity increased two-fold in RasV12 cells treated with U0126, the induction was not statistically significant. These results demonstrate that Ras/MEK suppresses the promoter activities of these MDII genes.
To identify the promoter region responsive to Ras/MEK, we conducted promoter deletion analysis of the Gbp2 and Ifi47 genes, which showed the most robust up-regulation by U0126 treatment (Figure 2b ). Deletion of 21-bp region between − 68 and − 47 of the Gbp2 promoter significantly reduced the U0126-induced transcriptional response, indicating that this region contains elements essential for transcriptional regulation of Gbp2. Similarly, we observed a significant reduction in U0126-induced activation of the Ifi47 promoter when the region from − 762 to − 148 or from − 148 to − 80 was deleted. Importantly, the deletion between − 148 and − 80 of the Ifi47 promoter completely abolished activation of its promoter activity by U0126. Regulation of Ifi47 transcription by IFN was primarily regulated by the same region (−762 to − 80) as regulated by U0126, although a region between − 80 and − 35 was also found to be responsive. In contrast, the elements responsible for regulation of Gbp2 by IFN are contained in regions from − 512 to − 83 and from − 83 to − 68 of the Gbp2 promoter, distinct from the U0126 responsive sites. These results suggest that independent promoter elements are required for MDII gene transcription by MEK inhibition compared with IFN stimulation.
We examined the Gbp2 and Ifi47 promoter regions essential for regulation by U0126 (Gbp2: − 68 to − 47 and Ifi47: − 148 and − 80) for transcription factor binding sites. Using the JASPAR database, we identified five putative transcription factor-binding sites (for paired box gene 2 (PAX2), IFN regulatory factor (IRF)-binding element (IRFE), AT rich interactive domain 3A (ARID3A), SRY-box containing gene 17 (SOX17) and SRY-box containing gene 10 (SOX10)) that were located in both of the U0126-responsive regions. Among the five candidate binding sites, we focused on the IRFE because of its relevance to the IFN system. 19 IRF1 regulates the transcription of MDII genes Chromatin immunoprecipitation (ChIP) assays were performed to determine whether IRF1 binds to the Gbp2 and Ifi47 gene promoters in response to MEK inhibition. We observed a relatively small amount of IRF1 present at the putative IRFE sites of Gbp2 and Ifi47 promoter in untreated RasV12 cells ( Figure 3a ). Treatment with either U0126 or IFN substantially enhanced IRF1 recruitment at the Gbp2 and Ifi47 promoter. This interaction was specific since the IRFE sites of Gbp2 and Ifi47 promoter regions were not detected in the pull-down with normal IgG, and binding of IRF1 to the distal control sites in the two promoters was not observed. These results demonstrate specific binding of IRF1 to the IRFE sites of Gbp2 and Ifi47 upon Ras/MEK inhibition in RasV12 cells. To validate and quantify these results, quantitative ChIP analysis was performed, which revealed that U0126 treatment significantly increased IRF1 binding at the IRFE sites of both Gbp2 and Ifi47 (Figure 3b ).
To determine if IRF1 regulates MDII gene expression in response to inhibiting the Ras/MEK pathway, we established primary and immortalized mouse embryonic fibroblasts (MEFs), which represent different stages of transformation, from wild type, or IRF1deficient, C57BL/6 mice. Expression of the MDII genes Gbp2 and Xaf1 was significantly induced by U0126 in primary wild type MEFs (Figure 4a ). In support of the role of IRF1 in regulating MDII genes, U0126 did not increase transcription of Gbp2 or Xaf1 in primary IRF1-deficient MEFs. In contrast, there was no upregulation of Ifi47, Il15 and Rig-I in wild type primary MEFs treated with U0126. Therefore, we examined the transcription of MDII genes in response to U0126 and IFN in immortalized MEFs, which are at a more advanced stage of transformation. Treatment with U0126 increased expression of all the MDII genes tested (Gbp2, Ifi47, Il15, Rig-I and Xaf1) in immortalized wild-type MEFs (Figure 4b ). This suggests that the degree of MDII gene induction by U0126 correlates with the level of cellular transformation and the level of IRF1 downregulation, which are in turn correlated with the degree of constitutive Ras activation. In contrast, induction of these genes was not observed in immortalized IRF1-deficient MEFs, confirming that IRF1 expression is necessary for this regulation. The absence of IRF1 also significantly reduced the induction of Ifi47, Il15 and Rig-I by IFN in both primary and immortalized MEFs and that of Gbp2 in primary MEFs and that of Xaf1 in immortalized MEFs, supporting the critical role of IRF1 in IFN-mediated transcription. 19 Taken together, these results demonstrated that IRF1 is the primary transcriptional regulator of these MDII genes. IRF1 expression is suppressed by the Ras/MEK pathway To determine how the Ras/MEK pathway regulates IRF1 function, we examined IRF1 expression in vector control NIH3T3 cells and RasV12 cells treated with or without U0126 (Figure 5a ). The expression level of IRF1 was lower in RasV12 cells than in vector control NIH3T3 cells and was restored by 6 h of MEK inhibition. Double bands of IRF1 were observed in vector control NIH3T3 cells, whereas only one band was apparent in RasV12 cells. We believe that the upper band is one of the IRF1 isoforms; however, it remains to be determined why it is present only in vector control cells. We also examined the mRNA and protein expression levels of IRF1 in RasV12 cells after treatment with U0126 ( Figure 5b ). RT-qPCR analysis revealed that the IRF1 mRNA level was significantly increased by MEK inhibition after 4 h of U0126 treatment, indicating that IRF1 mRNA levels are downregulated by the active Ras/MEK pathway. Similarly, we observed increased IRF1 protein levels as early as 2 h after U0126 treatment. These results demonstrated that the Ras/MEK pathway downregulates IRF1 expression at both the mRNA and protein levels.
To determine if regulation of IRF1 by Ras/MEK also occurs in human cancer cells, we analyzed the effect of MEK inhibition on IRF1 expression in the human breast carcinoma cells MDA-MB-468 and the human colon cancer cells DLD-1 (Figures 5c and d ). We found that IRF1 protein is upregulated in both MDA-MB-468 and DLD-1 cells after 24 h of treatment, even at sub-optimal concentrations of U0126, as determined by ERK phosphorylation levels. Furthermore, we found that IRF1 protein increased in response to three different MEK inhibitors (U0126, PD98059 and SL327), demonstrating that the regulation of IRF1 was not because of non-specific effects of U0126 (Figure 5d ). Knockdown of ERK 1/2 in RasV12 cells also increased the IRF1 expression levels, further supporting the interaction between Ras/MEK and IRF1 (Figure 5e ).
Ras/MEK-mediated downregulation of IRF1 impairs the IFN antiviral response
To determine whether IRF1 downregulation is the key factor in the impairment of antiviral response in cells with activated Ras/MEK, we restored IRF1 expression in RasV12 cells and in human cancer cells. First, to determine if IRF1 overexpression is sufficient to restore IFN-induced antiviral activity in RasV12 cells, the cells were transfected with either mouse IRF1 or control vector (pCMV-SPORT6), followed by treatment with different concentrations of IFN for 16 h and then challenged with vesicular stomatitis virus (VSV). IRF1 introduction restored IFN's ability to protect RasV12 cells from VSV infection, particularly with 120 and 60 U/ml of IFN (Figure 6a ).
Next, we determined whether IFN-sensitive oncolytic viruses exploit Ras-mediated IRF1 downregulation in human cancer cells by overexpressing IRF1 followed by infection with the oncolytic version of VSV (VSVM51R; AV1). 5 We found that the human cancer cell lines, HT1080 and HT29, were susceptible to the oncolytic virus when transfected with control vector (pCMV-SPORT6), but that viral oncolysis was severely restricted in a concentration dependent manner with overexpression of IRF1 (Figure 6b ). Next, human cancer DLD-1 cells were infected with different MOIs of VSVM51R after transfection with control or IRF1 vector (Figure 6c ). Similar to the results obtained above, the oncolytic virus replicated efficiently in cells transfected with control vector, whereas IRF1 overexpression substantially restricted viral oncolysis. Together these results demonstrated the critical role of IRF1 in defining the susceptibility of cancer cells to certain oncolytic viruses.
DISCUSSION
In our previous study, we reported that the transcription of a group of IFN-inducible genes was suppressed by Ras/MEK in human cancer cells, which we defined as MEK downregulated IFNinducible (MDII) genes. 18 In this study, we aimed to clarify the molecular mechanism underlying Ras/MEK-mediated downregulation of the MDII gene transcription. This study demonstrates that (1) IRF1 is the transcriptional regulator of MDII genes, (2) activated Ras/MEK reduces IRF1 expression in mouse fibroblast cells and human cancer cells and (3) the expression level of IRF1 modulates cellular susceptibility to viral oncolysis. IRF1, which was initially identified as a transcriptional activator of the IFN-β gene, has been found to be broadly involved in regulating gene transcription important for innate immune responses. [19] [20] [21] IRF1 is a potent antiviral effector, and deficient levels of this protein result in dramatically increased cellular susceptibility to different types of viruses. [22] [23] [24] In addition, IRF1 has been characterized as a tumor suppressor, which simultaneously upregulates the transcription of tumor suppressor genes, while downregulating the transcription of oncogenes to induce apoptosis and growth inhibition. 25 Therefore, it is likely that tumor cells acquire oncogenic cellular characteristics to dysregulate anti-tumor functions of IRF1 during their development. In fact, the IRF1 gene is often lost, mutated or downregulated in several types of cancer 26 and is negatively correlated with the tumor grade, risk of recurrence and death. 27, 28 Activating mutations of the Ras protein have been found in~30% of all human cancers. 29 Moreover, in cancers where direct activating mutations of Ras protein are absent, the upstream or downstream signaling components of the Ras pathway are often found to be over-active instead, 30 suggesting that Ras/MEK activation may underlie IRF1 impairment in a broad range of human cancer cells. Such observations suggest that the IRF1 downregulation may be a common aberrant characteristic in human cancer cells that can be exploited by Ras-dependent or IFN-sensitive oncolytic viruses.
As we show here, IRF1 is the key transcriptional regulator of the MDII genes that are responsible for the IFN-mediated antiviral response, IFN production or Jak/STAT activation (Figure 7) . Therefore, the low-expression IRF1/MDII genes in cancer cells results in a delay in establishing antiviral responses, and allows replication of oncolytic viruses. In contrast, normal cells expressing higher levels of IRF1, and therefore higher levels of IRF1-regulated MDII genes, can induce the antiviral response rapidly and efficiently upon oncolytic virus infection. In contrast to the initial stage of viral oncolysis that is promoted by IRF1/MDII genes-downregulation by MEK, other tumor-specific molecular changes may play critical roles in maintaining cancer cell susceptibility to oncolytic viruses at the later phase of infection when IFNs and cytokines are actively produced. As recently shown, the steady state levels of antiviral genes correlate with sensitivity of cancer cells to viral oncolysis. 31, 32 IRF1 stimulates its own transcription as a positive regulatory factor. 33 As IRF1 expression was restored earlier at the protein level than at the mRNA level in RasV12 cells treated with U0126 (Figure 5b ), we hypothesized that Ras/MEK inhibition restores IRF1 protein stability, which leads to the induction of IRF1 mRNA expression. However, this was not the case since U0126 treatment did not change IRF1 protein stability in cycloheximide-treated RasV12 cells and human cancer cells (Supplementary Figure S1) .
There are other possible ways that translation of IRF1 may be directly regulated by the Ras/MEK pathway. MicroRNAs can regulate protein synthesis by repressing translation or, in some cases, by promoting translation. 34, 35 In particular, miR-23a and miR-383 bind to the 3′-UTR of IRF1 mRNA to regulate both its mRNA and protein level. 36, 37 Ras/MEK may regulate the activity of an IRF1-binding microRNAs to suppress translation rate of IRF1 mRNA. Alternatively, Ras/MEK could regulate translation of IRF1 mRNA through the regulation of eIF4E, which is phosphorylated by the MAP-kinase signal-integrating kinases 1 and 2, both of which are downstream elements of Ras/MEK. 38 The effect of phosphorylation on eIF4E activity is controversial and may either reduce. 39 or increase 40 the binding affinity for the cap structure of mRNA. eIF4E phosphorylation also plays an important role in the translocation of certain mRNAs. 41, 42 IRF1 mRNA may be sensitive to eIF4E-regulated translation or translocation via the Mnk1/2-eIF4E. The precise mechanism of IRF1 regulation by Ras/MEK, however, remains to be elucidated.
Both Type I and Type II IFNs are known as a potent inducer of IRF1. 19 IRF1 promotion by Ras/MEK may be a secondary effect of IFN induction and activation of the IFN pathway. However, this is unlikely the case because MEK inhibition did not activate the Jak-STAT pathways 16 and because transcriptional activators of IFNs, such as IRF3 and IRF7, were not induced by U0126 treatment in the microarray analysis. Although further study is required, we believe that Ras/MEK directly regulates IRF1 expression at its transcriptional or translational level.
Within cancer cells, Ras activation and defects in the innate immune response are the two major cellular characteristics targeted by oncolytic viruses. Ras activation promotes replication of oncolytic viruses in multiple ways, such as inhibition of antiviral function of PKR, or enhancement of virus entry and uncoating, viral particle release and translation of viral mRNA. 3, 11, 14 Deficiencies in IFN signaling components 43 and epigenetic modifications of chromatin 44 have also been reported to contribute to the generation of a defective innate immune response. Here, we demonstrate that IRF1 downregulation is responsible for transcriptional suppression of IFN-inducible genes in cells with activated Ras/MEK. Although it remains to be determined whether the Ras/MEK-mediated downregulation of IRF1 expression underlies other oncolytic mechanisms previously reported, we believe that this may represent a common mechanism for a broad range of oncolytic viruses. Although IRF1 is a well-known tumor suppressor and antiviral protein, its involvement in viral oncolysis has never been investigated. Our findings will contribute toward the design of novel oncolytic viruses and their therapeutic uses for cancer treatment with improved efficacy and safety. Moreover, while IFN therapy has shown significant therapeutic effects on cancer patients with certain types of cancer, 45 its efficacy is often halted by the presence of cancer cells resistant to IFN therapy. 43, [46] [47] [48] Since IRF1 downregulation by Ras/MEK may underlie development of resistance to IFN stimulation, combined treatment with Ras/MEK inhibitors would improve the efficacy of IFN therapy in cancer patients.
MATERIALS AND METHODS
Cells and reagents
Murine fibroblast cells (NIH3T3 and L929) and human cancer cells (HT29, HT1080, DLD-1 and MDA-MB-468) were obtained from the American Type Culture Collection (Manassas, VA, USA) and immortalized wild type MEFs from Dr Nahum Sonenberg (McGill University, Montreal, Canada). All the human cancer cell lines used in this study were authenticated by DDC Medical (Fairfield, OH, USA) by STR DNA analysis. IRF1-deficient and wildtype MEFs were established from day 14 embryos of C57BL/6-Irf1 tm1Mak49 and C57BL/6J mice from the Jackson Laboratory (Bar Harbor, ME, USA). Immortalized IRF1-deficient MEFs were established by serial passages of primary MEFs over the course of seven passages over 21 days. Figure 7 . Schematic diagram illustrating the suppression of MDII gene expression by Ras/MEK via inhibition of IRF1. The expression of the MDII genes is regulated by the level of IRF1 expression, which is in turn regulated by Ras/MEK activity. The MDII genes are involved in promoting host defense against oncolytic viruses at the different stages, such as antiviral response (that is, Gbp2, Xaf1), IFN production (that is, Rig-I, Il15) and IFN sensitivity (that is, Stat2). The decreased expression of the MDII genes by Ras/MEK support replication of oncolytic virus in cancer cells, but not in normal cells. The relative expression levels of the proteins are symbolized by the size of the protein.
Recombinant mouse IFN-α was purchased from PBL Interferon Source (Piscataway, NJ, USA), U0126 from Cell Signaling Technology (Danvers, MA, USA) and PD98059 and SL327 from Calbiochem (La Jolla, CA, USA). Antibodies to VSV-G were purchased from Alpha Diagnostic (San Antonio, TX, USA), phospho-ERK 1/2 from Calbiochem, GAPDH (6C5) from Abcam (Toronto, ON, Canada), mouse IRF1 (M-20) and total ERK (sc-94) from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and human IRF1 from BD Transduction Laboratories (Mississauga, ON, Canada). Mouse IRF1 and human IRF1 cDNAs were purchased from Thermo Fisher Scientific (Waltham, MA, USA), pGL3-Basic vectors from Promega (Madison, WI, USA) and pISRE-Luc from Stratagene (La Jolla, CA, USA). ERK 1/2 siRNA and control siRNA were obtained from Santa Cruz Biotechnology and used as previously described. 16 DNA microarray analysis and quantitative RT-PCR RNA was isolated from RasV12 cells treated with 20 μM U0126 or 500 U/ml IFN-α, or left untreated, for 6 h. Total RNA treated with DNase using TURBO DNA-freeTM kit (Ambion, ON, Canada) were sent to the Centre for Applied Genomics (TCAG, Toronto, ON, Canada) for analysis using Affymetrix 430 2.0 mouse DNA microarrays (Affymetrix, Santa Clara, CA, USA). RNA integrity number was determined to be greater than 8.9 for all samples (Agilent 2100 Bioanalyzer, Agilent, Santa Clara, CA, USA). Data from three biological replicates were analyzed using GeneSpring (v7.3, Agilent). Genes with greater than 2.5-fold induction compared with the untreated control were compared using Venn diagrams. A fold-change cut-off strategy was used to reduce the Type II (false negative) error rate in order to identify all possible candidate genes. Data are deposited in the Gene expression omnibus 50 (GEO accession number GSE49469). Quantitative RT-PCR (RT-qPCR) was performed in triplicate using the previously described validation strategies. 18 The primer sequences are shown in Supplementary Table S1 .
Promoter reporter assays
Promoter constructs of Gbp2, Ifi47 and Rig-I were obtained by PCR amplification of mouse genomic DNA and ligation into the XhoI and HindIII sites of pGL3-Basic vector. The promoter deletion constructs of Gbp2 and Ifi47 were made using the Erase-a-Base System (Promega) according to the manufacturer's instructions followed by sequencing to determine the remaining promoter region. RasV12 cells were transiently transfected with 1 μg of the reporter plasmids using SuperFect Transfection Reagent (QIAGEN, Mississauga, ON, Canada). Twenty-four hours after transfection, cells were treated with U0126 or IFN-α for additional 24 h. Luciferase activity was measured by the Luciferase Assay System (Promega) and luminescence measured using Fluoroskan Ascent FL (Thermo Labsystems, Waltham, MA, USA). Transcription factor binding elements were identified using the JASPAR database. 51 
Virus infection
Wild-type VSV (Indiana strain) and attenuated VSV (VSVM51R), provided by Dr John C Bell (Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada) were amplified and titers determined as described previously. 4, 15 To generate IRF1-overexpressing cells, RasV12 cells were transfected with mouse IRF1 pCMV-SPORT6 or control pCMV-SPORT6 using SuperFect Transfection Reagent (QIAGEN). At 24 h after the transfection, the cells were treated with IFN-α for 16 h and then infected with VSV. IRF1-overexpressing human cancer cells were generated using human IRF1 pCMV-SPORT6 or control pCMV-SPORT6.
Chromatin immunoprecipitation assay
RasV12 cells treated with U0126 or IFN-α, or left untreated for 4 h were incubated with 37% formaldehyde for 10 min to cross-link chromatin and then treated with 0.125 M glycine to terminate the cross-linking. Cells were then washed twice with PBS, and the cell pellet was resuspended in ChIP lysis buffer (Santa Cruz Biotechnology) (1.0% SDS, 10.0 mM EDTA, 50 mM Tris-Hcl, pH 8.1). Chromatin was sonicated into 200-500-bp length fragments and incubated with 50 μl of Pierce Protein A Agarose beads (Thermo Scientific, Rockford, IL, USA) pre-blocked with Herring Sperm DNA (Life Technologies, Burlington, ON, Canada) and BSA (Promega). One milligram of the cell lysate was diluted to a final volume of 1 ml with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.20 mM EDTA, 16.7 mM Tris-HCl pH 8.1, 167 mM NaCl) supplemented with protease and phosphatase inhibitors (Aprotinin, Sigma-Aldrich, Oakville, ON, Canada), (PMSF, Sigma-Aldrich), (Halt Phosphatase Inhibitor Cocktail, Thermo Scientific) and was incubated with 4 μg of anti-IRF1 antibody or normal Rabbit IgG (Santa Cruz Biotechnology) overnight. The antibody-chromatin complexes were incubated with 50 μl of preblocked protein A agarose beads and washed twice each with low-salt wash buffer (0.1% SDS, 1.0% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), high-salt wash buffer (0.1% SDS, 1.0% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 500 mM NaCl), LiCl wash buffer (250 mM LiCl, 1.0% IGEPAL-CA630, 1% Deoxycholic Acid, 1.0 mM EDTA, 10.0 mM Tris pH 8.1), and TE buffer (10.0 mM Tris pH 8.1, 1.0 mM EDTA). The chromatin complex was then eluted from beads using elution buffer (1.0% SDS, 100.0 mM NaHCO 3 ), and treated with 5 M NaCl overnight. Samples were then treated with RNase A (QIAGEN) and Proteinase K (QIAGEN). ChIP end-point PCR and ChIP qPCR were performed using primers listed in Supplementary Table S2 and S3, respectively.
Western blot analysis
Protein samples were prepared and western blot was conducted and evaluated as previously described 15 using antibodies listed above.
Statistical analysis
One-way analysis of variance with Tukey's post-hoc test were performed using GraphPad Prism 4.0c software (GraphPad Software, La Jolla, CA, USA).
